Biofrontera Analyst Price Targets - Benzinga

Biofrontera Inc

BFRINASDAQ

Trade with Public

Trade with Public

$1.55

0.096.16%

al cierre: Sep 11, 5:00 PM EST

$1.59

0.042.58%

After hour: 7:57 PM EST

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Comparar Informe de acciones

Biofrontera Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biofrontera (BFRI).

Price Target Range — 4 Quarters

Analyst Consensus

Consensus RatingBuyAvg. Consensus PT$3Upside to Avg. PT+81.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 19, 2026	Benchmark	Bruce D. Jackson	Downgrade	Buy→Speculative Buy	$3
May 19, 2025	Benchmark	Bruce Jackson	PT Cut	Buy	$7→$3
Nov 15, 2024	Benchmark	Bruce Jackson	Maintained	Buy	$7
Aug 16, 2024	Benchmark	Bruce Jackson	Maintained	Buy	$7

More with Benzinga EdgeGet Access

Analyst Ratings News

This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.

Avi Kapoor

This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.

Avi Kapoor

PRO
Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3

Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.

Benzinga Newsdesk

PRO
Benchmark Maintains Buy on Biofrontera, Lowers Price Target to $2.75

Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.

Benzinga Newsdesk

PRO
Benchmark Reiterates Buy on Biofrontera, Maintains $7 Price Target

Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Buy on Biofrontera, Maintains $7 Price Target

Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and maintains $7 price target.

Benzinga Newsdesk